688073 毕得医药
已收盘 05-19 15:00:01
资讯
新帖
简况
毕得医药(688073)披露股东减持股份计划公告,5月19日股价下跌4.17%
证券之星 · 05-19 17:50
毕得医药(688073)披露股东减持股份计划公告,5月19日股价下跌4.17%
毕得医药(688073)披露2025年年度股东会决议公告,5月14日股价下跌3.11%
证券之星 · 05-14
毕得医药(688073)披露2025年年度股东会决议公告,5月14日股价下跌3.11%
股市必读:毕得医药一季报 - 第一季度单季净利润同比增长52.57%
证券之星 · 05-06
股市必读:毕得医药一季报 - 第一季度单季净利润同比增长52.57%
每周股票复盘:毕得医药(688073)股东减持2.84%股份
证券之星 · 05-02
每周股票复盘:毕得医药(688073)股东减持2.84%股份
毕得医药(688073)2026年一季报简析:营收净利润同比双双增长,盈利能力上升
证券之星 · 05-01
毕得医药(688073)2026年一季报简析:营收净利润同比双双增长,盈利能力上升
4月30日毕得医药涨6.35%,信澳信用债债券A基金重仓该股
证券之星 · 04-30
4月30日毕得医药涨6.35%,信澳信用债债券A基金重仓该股
毕得医药涨6.35%,开源证券一个月前给出“买入”评级
证券之星 · 04-30
毕得医药涨6.35%,开源证券一个月前给出“买入”评级
4月28日毕得医药发布公告,股东减持53.88万股
证券之星 · 04-28
4月28日毕得医药发布公告,股东减持53.88万股
股市必读:4月24日毕得医药现1笔折价16.76%的大宗交易 合计成交606.64万元
证券之星 · 04-27
股市必读:4月24日毕得医药现1笔折价16.76%的大宗交易 合计成交606.64万元
4月24日毕得医药现1笔折价16.76%的大宗交易 合计成交606.64万元
证券之星 · 04-24
4月24日毕得医药现1笔折价16.76%的大宗交易 合计成交606.64万元
图解毕得医药年报:第四季度单季净利润同比下降4.67%
证券之星 · 04-23
图解毕得医药年报:第四季度单季净利润同比下降4.67%
4月22日毕得医药发布公告,股东减持97.86万股
证券之星 · 04-22
4月22日毕得医药发布公告,股东减持97.86万股
4月20日毕得医药现4笔大宗交易 机构净买入1004.49万元
证券之星 · 04-20
4月20日毕得医药现4笔大宗交易 机构净买入1004.49万元
每周股票复盘:机构净买入毕得医药(688073)634.6万元
证券之星 · 04-19
每周股票复盘:机构净买入毕得医药(688073)634.6万元
4月15日毕得医药现8笔大宗交易 机构净买入634.6万元
证券之星 · 04-15
4月15日毕得医药现8笔大宗交易 机构净买入634.6万元
毕得医药(688073)4764.88万股限售股将于4月13日解禁,占总股本52.43%
证券之星 · 04-13
毕得医药(688073)4764.88万股限售股将于4月13日解禁,占总股本52.43%
每周股票复盘:毕得医药(688073)股东减持10.01万股占总股本0.11%
证券之星 · 04-12
每周股票复盘:毕得医药(688073)股东减持10.01万股占总股本0.11%
4月7日毕得医药发布公告,股东减持10.01万股
证券之星 · 04-07
4月7日毕得医药发布公告,股东减持10.01万股
每周股票复盘:毕得医药(688073)4765万股限售股将上市
证券之星 · 04-05
每周股票复盘:毕得医药(688073)4765万股限售股将上市
毕得医药(688073)披露首次公开发行部分限售股上市流通公告,4月3日股价下跌5.26%
证券之星 · 04-03
毕得医药(688073)披露首次公开发行部分限售股上市流通公告,4月3日股价下跌5.26%
加载更多
公司概况
公司名称:
上海毕得医药科技股份有限公司
所属行业:
研究和试验发展
上市日期:
2022-10-11
主营业务:
上海毕得医药科技股份有限公司的主营业务是药物分子砌块和科学试剂的研发、设计、生产及销售。公司的主要产品是分子砌块杂环化合物、分子砌块苯环化合物、分子砌块脂肪族类化合物、催化剂和配体、生命科学试剂。截至报告期末,公司知识产权项目获得授权数量148个,其中发明专利59个,实用新型专利24个,外观设计专利1个,软件著作权2个,其他62个。
发行价格:
88.00
{"stockData":{"symbol":"688073","market":"SH","secType":"STK","nameCN":"毕得医药","latestPrice":51.99,"timestamp":1779174001000,"preClose":54.25,"halted":0,"volume":2560203,"delay":0,"changeRate":-0.0417,"floatShares":90882900,"shares":90882900,"eps":1.8472,"marketStatus":"已收盘","change":-2.26,"latestTime":"05-19 15:00:01","open":52.9,"high":53.1,"low":50.89,"amount":133000000,"amplitude":0.0407,"askPrice":52,"askSize":3,"bidPrice":51.99,"bidSize":8,"shortable":0,"etf":0,"ttmEps":1.8472,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779240600000},"marketStatusCode":5,"adr":0,"adjPreClose":54.25,"symbolType":"stock_kcb","openAndCloseTimeList":[[1779154200000,1779161400000],[1779166800000,1779174000000]],"highLimit":59.68,"lowLimit":48.83,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":90882948,"isCdr":false,"pbRate":2.25,"roa":"--","peRate":28.145301,"roe":"2.26%","epsLYR":1.75,"committee":0.459459,"marketValue":4725000000,"turnoverRate":0.0282,"status":1,"afterMarket":{"amount":0,"volume":0,"close":51.99,"buyVolume":200,"sellVolume":0,"time":1779176037558,"indexStatus":"已收盘 05-19 15:30:00","preClose":54.25},"floatMarketCap":4725000000},"requestUrl":"/m/hq/s/688073","defaultTab":"news","newsList":[{"id":"2636832919","title":"毕得医药(688073)披露股东减持股份计划公告,5月19日股价下跌4.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636832919","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636832919?lang=zh_cn&edition=full","pubTime":"2026-05-19 17:50","pubTimestamp":1779184225,"startTime":"0","endTime":"0","summary":"截至2026年5月19日收盘,毕得医药报收于51.99元,较前一交易日下跌4.17%,最新总市值为47.25亿元。公司于近日披露《股东减持股份计划公告》。欣曦管理拟减持不超过1,363,243股,兰旦管理拟减持不超过1,181,477股,吴波拟减持不超过181,766股,合计减持比例不超过公司总股本的3.00%。本次减持计划符合相关法律法规规定,不会导致公司控制权变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900034144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635552713","title":"毕得医药(688073)披露2025年年度股东会决议公告,5月14日股价下跌3.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635552713","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635552713?lang=zh_cn&edition=full","pubTime":"2026-05-14 18:00","pubTimestamp":1778752844,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘,毕得医药报收于55.8元,较前一交易日下跌3.11%,最新总市值为50.71亿元。公司于近日披露《2025年年度股东会决议公告》。公告显示,上海毕得医药科技股份有限公司于2026年5月13日召开2025年年度股东会,会议由董事长戴岚主持,采用现场与网络投票结合方式举行。出席会议股东共44人,代表有表决权股份总数1,727,925股,占公司总表决权股份的2.0057%。所有议案均获通过,无否决议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400034038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633792767","title":"股市必读:毕得医药一季报 - 第一季度单季净利润同比增长52.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633792767","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633792767?lang=zh_cn&edition=full","pubTime":"2026-05-06 05:20","pubTimestamp":1778016024,"startTime":"0","endTime":"0","summary":"来自业绩披露要点:毕得医药2026年一季度归母净利润达4682.91万元,同比增长52.57%。股本股东变化股东户数变动近日毕得医药披露,截至2026年3月31日公司股东户数为4924.0户,较12月31日增加1032.0户,增幅为26.52%。业绩披露要点财务报告毕得医药2026年一季报显示,一季度公司主营收入3.23亿元,同比上升9.08%;归母净利润4682.91万元,同比上升52.57%;扣非净利润3992.46万元,同比上升42.21%;负债率17.39%,投资收益40.41万元,财务费用1266.38万元,毛利率48.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600003745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623855","title":"每周股票复盘:毕得医药(688073)股东减持2.84%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623855","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632623855?lang=zh_cn&edition=full","pubTime":"2026-05-02 05:47","pubTimestamp":1777672031,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,毕得医药报收于63.52元,较上周的55.86元上涨13.71%。来自股本股东变化:2026年4月21日至4月27日,股东欣曦管理、兰旦管理合计减持53.88万股,占总股本0.5929%。截至届满,欣曦管理减持1,399,596股,占总股本1.54%;兰旦管理减持1,145,068股,占总股本1.26%;吴波减持37,419股,占总股本0.04%;合计减持2,582,083股,占总股本2.84%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632660424","title":"毕得医药(688073)2026年一季报简析:营收净利润同比双双增长,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2632660424","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632660424?lang=zh_cn&edition=full","pubTime":"2026-05-01 06:46","pubTimestamp":1777589161,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期毕得医药发布2026年一季报。截至本报告期末,公司营业总收入3.23亿元,同比上升9.08%,归母净利润4682.91万元,同比上升52.57%。本报告期毕得医药盈利能力上升,毛利率同比增幅10.26%,净利率同比增幅39.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050100007139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631416685","title":"4月30日毕得医药涨6.35%,信澳信用债债券A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2631416685","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631416685?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:24","pubTimestamp":1777537499,"startTime":"0","endTime":"0","summary":"证券之星消息,4月30日毕得医药涨6.35%,收盘报63.52元,换手率5.1%,成交量4.64万手,成交额2.92亿元。重仓毕得医药的公募基金请见下表:该股最近90天内共有2家机构给出评级,买入评级2家。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共8家,其中持有数量最多的公募基金为信达澳亚基金的信澳信用债债券A。信澳信用债债券A目前规模为24.39亿元,最新净值1.341,较上一交易日上涨0.52%,近一年上涨22.35%。该公募基金现任基金经理为张旻。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000053260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073","159397"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631668579","title":"毕得医药涨6.35%,开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2631668579","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631668579?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:24","pubTimestamp":1777537485,"startTime":"0","endTime":"0","summary":"今日毕得医药涨6.35%,收盘报63.52元。2026年3月2日,开源证券研究员余汝意,石启正发布了对毕得医药的研报《公司信息更新报告:2025年业绩表现亮眼,经营态势稳步向好》,该研报对毕得医药给出“买入”评级。研报中预计公司2025-2027年归母净利润为1.52/2.27/2.84亿,对应EPS分别为1.68/2.50/3.13元/股,当前股价对应PE为34.8/23.3/18.6倍,维持“买入”评级。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为华创证券的万梦蝶。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000053252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630309810","title":"4月28日毕得医药发布公告,股东减持53.88万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630309810","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630309810?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:38","pubTimestamp":1777376299,"startTime":"0","endTime":"0","summary":"证券之星消息,4月28日毕得医药发布公告《毕得医药:股东减持计划时间届满暨减持股份结果公告》,其股东舟山欣曦企业管理合伙企业(有限合伙)、舟山兰旦企业管理合伙企业(有限合伙)于2026年4月21日至2026年4月27日间合计减持53.88万股,占公司目前总股本的0.5929%,变动期间该股股价下跌9.12%,截止4月27日收盘报55.53元。股东增减持详情见下表:根据毕得医药2025年年报公布的十大股东详情如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800055870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630334784","title":"股市必读:4月24日毕得医药现1笔折价16.76%的大宗交易 合计成交606.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630334784","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630334784?lang=zh_cn&edition=full","pubTime":"2026-04-27 07:24","pubTimestamp":1777245854,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘,毕得医药报收于55.86元,下跌2.85%,换手率1.42%,成交量1.29万手,成交额7302.19万元。交易信息汇总资金流向4月24日主力资金净流出308.08万元,占总成交额4.22%;游资资金净流出442.41万元,占总成交额6.06%;散户资金净流入750.49万元,占总成交额10.28%。大宗交易4月24日毕得医药现1笔折价16.76%的大宗交易,合计成交606.64万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700007115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629789817","title":"4月24日毕得医药现1笔折价16.76%的大宗交易 合计成交606.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629789817","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629789817?lang=zh_cn&edition=full","pubTime":"2026-04-24 18:17","pubTimestamp":1777025848,"startTime":"0","endTime":"0","summary":"证券之星消息,4月24日毕得医药发生大宗交易,交易数据如下:近三个月该股共发生32笔大宗交易,合计成交1.77万手,折价成交32笔。该股在过去半年内已有共计4764.88万股限售解禁股上市,占公司总股本的52.43%。截至2026年4月24日收盘,毕得医药报收于55.86元,下跌2.85%,换手率1.42%,成交量1.29万手,成交额7302.19万元。该股近半年内有股东持股变动,合计净减持316.58万股,股东增减持明细如下表:该股最近90天内共有2家机构给出评级,买入评级2家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400054835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629029424","title":"图解毕得医药年报:第四季度单季净利润同比下降4.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629029424","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629029424?lang=zh_cn&edition=full","pubTime":"2026-04-23 01:21","pubTimestamp":1776878484,"startTime":"0","endTime":"0","summary":"证券之星消息,毕得医药2025年年报显示,当年度公司主营收入13.24亿元,同比上升20.13%;归母净利润1.52亿元,同比上升29.22%;扣非净利润1.32亿元,同比上升27.2%;其中2025年第四季度,公司单季度主营收入3.45亿元,同比上升18.6%;单季度归母净利润3200.56万元,同比下降4.67%;单季度扣非净利润2985.64万元,同比下降5.61%;负债率18.73%,投资收益798.33万元,财务费用1466.23万元,毛利率44.54%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300002651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629417150","title":"4月22日毕得医药发布公告,股东减持97.86万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629417150","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629417150?lang=zh_cn&edition=full","pubTime":"2026-04-22 21:01","pubTimestamp":1776862865,"startTime":"0","endTime":"0","summary":"证券之星消息,4月22日毕得医药发布公告《毕得医药:关于股东权益变动触及1%刻度的提示性公告》,其股东吴波、舟山欣曦企业管理合伙企业(有限合伙)、舟山兰旦企业管理合伙企业(有限合伙)于2026年3月9日至2026年4月20日间合计减持97.86万股,占公司目前总股本的1.0768%,变动期间该股股价上涨6.06%,截止4月20日收盘报61.1元。股东增减持详情见下表:根据毕得医药2025年三季报公布的十大股东详情如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200051770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628584746","title":"4月20日毕得医药现4笔大宗交易 机构净买入1004.49万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628584746","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628584746?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:21","pubTimestamp":1776676872,"startTime":"0","endTime":"0","summary":"证券之星消息,4月20日毕得医药发生大宗交易,交易数据如下:近三个月该股共发生26笔大宗交易,合计成交1.4万手,折价成交26笔。该股在过去半年内已有共计4764.88万股限售解禁股上市,占公司总股本的52.43%。截至2026年4月20日收盘,毕得医药报收于61.1元,上涨1.34%,换手率1.59%,成交量1.45万手,成交额8936.2万元。该股近半年内有股东持股变动,合计净减持218.72万股,股东增减持明细如下表:该股最近90天内共有2家机构给出评级,买入评级2家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000023895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628594537","title":"每周股票复盘:机构净买入毕得医药(688073)634.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628594537","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628594537?lang=zh_cn&edition=full","pubTime":"2026-04-19 02:49","pubTimestamp":1776538146,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘,毕得医药(688073)报收于60.29元,较上周的62.67元下跌3.8%。本周,毕得医药4月15日盘中最高价报63.68元。4月14日盘中最低价报59.41元。毕得医药当前最新总市值54.79亿元,在医疗服务板块市值排名36/51,在两市A股市值排名3278/5198。本周关注点来自交易信息汇总:4月15日毕得医药现8笔大宗交易,机构净买入634.6万元交易信息汇总4月15日毕得医药现8笔大宗交易,机构净买入634.6万元以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900000949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627400811","title":"4月15日毕得医药现8笔大宗交易 机构净买入634.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627400811","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627400811?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:22","pubTimestamp":1776244976,"startTime":"0","endTime":"0","summary":"证券之星消息,4月15日毕得医药发生大宗交易,交易数据如下:近三个月该股共发生22笔大宗交易,合计成交1.22万手,折价成交22笔。该股在过去半年内已有共计4764.88万股限售解禁股上市,占公司总股本的52.43%。截至2026年4月15日收盘,毕得医药报收于62.7元,上涨1.8%,换手率1.92%,成交量1.74万手,成交额1.08亿元。该股近半年内有股东持股变动,合计净减持218.72万股,股东增减持明细如下表:该股最近90天内共有2家机构给出评级,买入评级2家。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041500031410.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627710286","title":"毕得医药(688073)4764.88万股限售股将于4月13日解禁,占总股本52.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627710286","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627710286?lang=zh_cn&edition=full","pubTime":"2026-04-13 08:02","pubTimestamp":1776038537,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,毕得医药于4月13日将有4764.88万股限售股份解禁,为公司追加承诺限售股份上市流通,占公司总股本52.43%。本次解禁后,公司已无限售股份。毕得医药主营业务:药物分子砌块和科学试剂业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041300001011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626122458","title":"每周股票复盘:毕得医药(688073)股东减持10.01万股占总股本0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2626122458","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626122458?lang=zh_cn&edition=full","pubTime":"2026-04-12 02:07","pubTimestamp":1775930828,"startTime":"0","endTime":"0","summary":"本周关注点股本股东变化:股东李怡静、耿勇、陈俊、蒋亚妹合计减持10.01万股,占公司总股本0.1102%。上述股东计划通过集中竞价方式减持不超过公司总股本0.95%的股份。前述股东合计减持100,119股,占公司总股本的0.11%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000590.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625930624","title":"4月7日毕得医药发布公告,股东减持10.01万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2625930624","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625930624?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:01","pubTimestamp":1775563278,"startTime":"0","endTime":"0","summary":"证券之星消息,4月7日毕得医药发布公告《毕得医药:股东减持计划完成暨减持股份结果公告》,其股东李怡静、耿勇、陈俊、蒋亚妹于2026年1月7日至2026年4月6日间合计减持10.01万股,占公司目前总股本的0.1102%,变动期间该股股价下跌11.88%,截止4月3日收盘报58.69元。股东增减持详情见下表:根据毕得医药2025年三季报公布的十大股东详情如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700028737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625162416","title":"每周股票复盘:毕得医药(688073)4765万股限售股将上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2625162416","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625162416?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:28","pubTimestamp":1775327291,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,毕得医药报收于58.69元,较上周的55.13元上涨6.46%。本周,毕得医药4月1日盘中最高价报62.91元。来自公司公告汇总:毕得医药首次公开发行部分限售股47,648,776股将于2026年4月13日上市流通,占总股本52.43%。交易信息汇总4月2日毕得医药发生3笔大宗交易,机构净买入231.25万元。公司首次公开发行后总股本为64,916,392股,经2022年度资本公积转增股本后总股本变更为90,882,948股。本次限售股上市流通后,相关股东持股比例相应减少,剩余限售股数量为0。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688073"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624732659","title":"毕得医药(688073)披露首次公开发行部分限售股上市流通公告,4月3日股价下跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624732659","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624732659?lang=zh_cn&edition=full","pubTime":"2026-04-03 17:49","pubTimestamp":1775209752,"startTime":"0","endTime":"0","summary":"公司于近日披露《首次公开发行部分限售股上市流通公告》。公告显示,上海毕得医药科技股份有限公司首次公开发行部分限售股将于2026年4月13日上市流通,本次上市流通数量为47,648,776股,占公司总股本的52.43%。公司首次公开发行后总股本为64,916,392股,经2022年度资本公积转增股本后总股本变更为90,882,948股。本次限售股上市流通后,相关股东持股比例相应减少,剩余限售股数量为0。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300034725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688073","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779214102452,"stockEarnings":[{"period":"1week","weight":-0.1271},{"period":"1month","weight":-0.1377},{"period":"3month","weight":-0.1294},{"period":"6month","weight":-0.3172},{"period":"1year","weight":0.2605},{"period":"ytd","weight":-0.1484}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0292},{"period":"3month","weight":0.0214},{"period":"6month","weight":0.0607},{"period":"1year","weight":0.2381},{"period":"ytd","weight":0.0506}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海毕得医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"4924人(较上一季度增加26.52%)","perCapita":"18457股","listingDate":"2022-10-11","address":"上海市杨浦区翔殷路128号11号楼A座101室","registeredCapital":"9088万元","survey":" 上海毕得医药科技股份有限公司的主营业务是药物分子砌块和科学试剂的研发、设计、生产及销售。公司的主要产品是分子砌块杂环化合物、分子砌块苯环化合物、分子砌块脂肪族类化合物、催化剂和配体、生命科学试剂。截至报告期末,公司知识产权项目获得授权数量148个,其中发明专利59个,实用新型专利24个,外观设计专利1个,软件著作权2个,其他62个。","listedPrice":88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"毕得医药(688073)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供毕得医药(688073)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"毕得医药,688073,毕得医药股票,毕得医药股票老虎,毕得医药股票老虎国际,毕得医药行情,毕得医药股票行情,毕得医药股价,毕得医药股市,毕得医药股票价格,毕得医药股票交易,毕得医药股票购买,毕得医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"毕得医药(688073)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供毕得医药(688073)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}